INDICATION AND LIMITATION OF USE

Vyvanse® (lisdexamfetamine dimesylate) is indicated for the treatment of ADHD in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

Vyvanse® (lisdexamfetamine dimesylate) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, and for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

This site is intended for US healthcare professionals only.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

  • CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing; monitor for signs of abuse and dependence during therapy.
Full Safety Information Below

Vyvanse® (lisdexamfetamine dimesylate) is indicated for the treatment of ADHD in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

Vyvanse® (lisdexamfetamine dimesylate) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, and for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

IMPORTANT SAFETY INFORMATION    This site is intended for US healthcare professionals only.

WARNING: ABUSE AND DEPENDENCE

  • | CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing; monitor for signs of abuse and dependence during therapy.
Full Safety Information Below

Vyvanse Pro Resource Center

The Pro Resource Center focuses on providing information and resources that complement the work you do with your ADHD adult patients. Whether your patients need help understanding co-pay costs or tracking symptoms, our Pro Resource Center can help provide you with patient-friendly resources. Use the tools below to learn more.

  • Look up Vyvanse Coverage and Co-pay Information

    Vyvanse has Tier 2 / Preferred formulary status for 82% of commercial plans in the US*

    Check patient’s individual health plan coverage and costs as plan status may change without notice.

    *Data Provided by Fingertip Formulary and is current as of [Date]. Total number of Commercial lives showing Tier 1, Tier 2, or Tier 3 Preferred tier status (excluding any plans showing a reason code of 93 or 94 - State Medicaid non-preferred) divided by the total number of Commercial lives nationally (excluding any plans showing total lives as Not Available). Check patient’s individual health plan as plan status and coverage may change without notice.

    Formulary results for

    Health plan provider:

    Status:

    Co-pay:

    Available health plan information:


    Health plan:

    Results data are provided by Fingertip Formulary® as of .

    Tier (Tier#) = A formulary category that determines the amount of co-pay required for a drug. The number of tiers varies by plan and can range from 1 to 7.

    Prior authorization (PA) = Approval process in which a prescriber must justify the use of a prescribed medication.

    Step edit (SE) = Prescription for a medication is filled only after treatment failure on one or more alternatives.

    Not covered (NC) = Drugs that are not covered by the plan.

    Not available (NA) = Data are not available.

  • Enroll Eligible Patients for a Savings Offer*

    Only licensed healthcare professionals may register. Complete the form to download a printable savings offer for your eligible patient. If you are not a healthcare professional, visit vyvansesavings.com.

    • *Restrictions apply. See savings offer for details.

    Required fields. Step 1 of 2 Step 2 of 2

      If you are a patient, visit vyvansesavings.com.

      Shire US Inc. will not sell or provide your e-mail information to other parties without your permission. This information will not be used for any purpose other than what is explained in our Privacy Policy Statement, available by clicking on this link: Review Shire Privacy Policy Statement. This consent will be in effect until such time as you opt out of the program.

      Thank You!

      Need to download another savings offer? Start Here.

    • Register With VyvansePro to Stay Informed

      Sign up for Shire’s program for healthcare professionals to receive regular communications with important information and news. These resources are specifically designed for healthcare professionals like you. Simply complete the form below and click submit.

      Required fields. Step 1 of 2 Step 2 of 2

        Shire respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Policy Statement. We encourage you to read our Privacy Policy Statement by clicking on this link: Review Shire Privacy Policy Statement. This consent will be in effect until such time as you opt out of the program.

        Thank You for registering!

      HAVE A QUESTION? Request a representative to get answers

      Thank you for your request.

      A Vyvanse representative will be contacting you shortly.

        How would you like to be contacted?

        Educational resources for you and your adult patients

        These educational resources are available to help you facilitate a more meaningful and informed discussion about ADHD and reimbursement with your patients.

        EDUCATIONAL DOWNLOADS

        WORKING WITH YOUR PATIENTS

        • Symptom Checklist For Adults

          Use this symptom checklist for discussing ADHD with your adult patients

          Download
        • Proper Medication Use Guide

          Help your patients understand the proper use of stimulant medications for ADHD

          Download

        IMPORTANT SAFETY INFORMATION

        WARNING: ABUSE AND DEPENDENCE

        • CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing; monitor for signs of abuse and dependence during therapy.
        • Contraindications
          Patients should not take Vyvanse if they are:
          • hypersensitive to amphetamines or other ingredients of Vyvanse. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have occurred.
          • taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis.
        • Warnings and Precautions
          • Prior to and during treatment assess for the presence of cardiac disease. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Note that sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulants at recommended doses, as well as sudden death in children and adolescents with structural cardiac abnormalities and other serious heart problems while taking CNS stimulants at recommended doses. Evaluate patients with exertional chest pain, unexplained syncope, or arrhythmias while taking Vyvanse.
          • CNS stimulants can cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
          • Prior to treatment assess for the presence of bipolar disorder. CNS stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychosis.
          • CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Monitor weight and height in children during treatment with Vyvanse. Treatment may need to be interrupted in children not growing as expected.
          • CNS stimulants, including Vyvanse, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Observe patients for new numbness, pain, skin color change, or sensitivity to temperature in fingers and toes. Further evaluation may be required, including referral.
          • Increased risk of serotonin syndrome when co-administered with serotonergic agents (eg, SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort), but also during overdosage situations. The potential for a pharmacokinetic interaction exists with co-administration of CYP2D6 inhibitors which may increase the risk with increased exposure to the active metabolite of Vyvanse (dextroamphetamine). In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6. If serotonin syndrome occurs, discontinue Vyvanse and any concomitant serotonergic agents immediately and initiate supportive treatment.
        • Adverse Reactions
          The most common adverse reactions (≥5% and at least twice the rate of placebo) reported in clinical trials were:
          • Children aged 6 to 12: decreased appetite, insomnia, upper abdominal pain, irritability, vomiting, decreased weight, nausea, dry mouth, and dizziness;
          • Adolescents aged 13 to 17: decreased appetite, insomnia, and decreased weight;
          • Adults: decreased appetite, insomnia, dry mouth, diarrhea, nausea, anxiety, and anorexia.
        • Pregnancy and Lactation
          Vyvanse may cause fetal harm. Breastfeeding is not recommended during Vyvanse treatment.

        INDICATION AND LIMITATION OF USE

        Vyvanse (lisdexamfetamine dimesylate) is indicated for the treatment of ADHD in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

        Please click here for Full Prescribing Information, including Boxed WARNING regarding Potential for Abuse and Dependence.

        IMPORTANT SAFETY INFORMATION

        WARNING: ABUSE AND DEPENDENCE

        • CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing; monitor for signs of abuse and dependence during therapy.
        • Contraindications
          Patients should not take Vyvanse if they are:
          • hypersensitive to amphetamines or other ingredients of Vyvanse. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have occurred.
          • taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis.
        • Warnings and Precautions
          • Prior to and during treatment assess for the presence of cardiac disease. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Note that sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulants at recommended doses, as well as sudden death in children and adolescents with structural cardiac abnormalities and other serious heart problems while taking CNS stimulants at recommended doses. Evaluate patients with exertional chest pain, unexplained syncope, or arrhythmias while taking Vyvanse.
          • CNS stimulants can cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
          • Prior to treatment assess for the presence of bipolar disorder. CNS stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychosis.
          • CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD. Monitor weight and height in children during treatment with Vyvanse for ADHD. Treatment may need to be interrupted in children not growing as expected.
          • CNS stimulants, including Vyvanse, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Observe patients for new numbness, pain, skin color change, or sensitivity to temperature in fingers and toes. Further evaluation may be required, including referral.
          • Increased risk of serotonin syndrome when co-administered with serotonergic agents (eg, SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort), but also during overdosage situations. The potential for a pharmacokinetic interaction exists with co-administration of CYP2D6 inhibitors which may increase the risk with increased exposure to the active metabolite of Vyvanse (dextroamphetamine). In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6. If serotonin syndrome occurs, discontinue Vyvanse and any concomitant serotonergic agents immediately and initiate supportive treatment.
        • Adverse Reactions
          The most common adverse reactions (≥5% and at least twice the rate of placebo) reported in ADHD clinical trials were:
          • Children aged 6 to 12: decreased appetite, insomnia, upper abdominal pain, irritability, vomiting, decreased weight, nausea, dry mouth, and dizziness;
          • Adolescents aged 13 to 17: decreased appetite, insomnia, and decreased weight;
          • Adults: decreased appetite, insomnia, dry mouth, diarrhea, nausea, anxiety, and anorexia.

          The most common adverse reactions (≥5% and at least twice the rate of placebo) reported in clinical trials of adults with moderate to severe B.E.D. were: dry mouth, insomnia, decreased appetite, increased heart rate, feeling jittery, constipation, and anxiety.

        • Pregnancy and Lactation
          Vyvanse may cause fetal harm. Breastfeeding is not recommended during Vyvanse treatment.
        • Other Considerations
          • Safety and effectiveness in patients <18 years with B.E.D. have not been established.

        INDICATION AND LIMITATION OF USE

        Vyvanse® (lisdexamfetamine dimesylate) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, and for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity has not been established.

        Please click here for Full Prescribing Information, including Boxed WARNING regarding Potential for Abuse and Dependence.

        You are about to leave vyvansepro.com.

        Please be advised that Shire has no control over the content or presentation of the site you are about to view.

        Cancel Continue
        CLOSE
        Scroll for additional Important Safety Info & see Full Prescribing Information.